One-Liner
A chronic-kidney-disease medication management companion for IgAN patients on new subcutaneous therapies like Trutakna, helping them track injections, at-home urinalysis, and nephrologist appointments.
AI Thinking Process
FDA approved Trutakna (atacicept) for IgAN 2026-07-08. Second FDA-approved chronic IgAN monoclonal in a wave. IgAN prevalence ~130-150K US, ~30-40K addressable high-risk. Weekly injection + biweekly urinalysis + quarterly nephrologist visit creates multi-track adherence pain.
Cricket Health/Somatus, StrivePCH, Monogram Health all value-based-care for insurers, not patient-facing companions. No injection-tracking app for Sparsentan/Fabhalta exists; Trutakna too new. Consumer rare-disease platforms (RareGuru, Belong.Life) exist but not nephrology-specific.
G207 TAM Ceiling pre-check fired: 30-40K addressable patients × 30% adoption × $15/mo = $1.6-2.2M ARR consumer ceiling. Manufacturer hub-service route at $200/patient-year × 10K = $2M. Combined ~$4-5M ARR. Below $10M threshold. G207 gate fires.
TAM expansion pivot: cross-nephrology (Fabhalta + Sparsentan + Trutakna). Total IgAN + FSGS + C3G = ~200K high-risk. But expanded scope loses wedge sharpness and overlaps with RareGuru and Belong.Life.
KILLED: TAM ceiling verified under $10M ARR at single-drug scope; expanded scope loses wedge. G207 gate fires as designed. Also fails G005 death guard — 'AI reminds you to take your injection' is the form-filling template disguised as chronic care.
Kill Reason
Maximum addressable revenue is under $10M ARR even after expanding scope to cover all rare nephrology drugs. Single-drug companion apps structurally cap out because disease populations are small. At 30-40K addressable US high-risk IgAN patients × 10% adoption × $15/month = $1.6-2.2M ARR consumer ceiling. Adding manufacturer patient-support program revenue brings combined ceiling to $4-5M ARR — still under the threshold. Expanding to cross-rare-nephrology companion loses the wedge and overlaps with generic rare-disease platforms.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.